Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dr. Reddy's Laboratories Ltd ADR
(NY:
RDY
)
81.77
+0.24 (+0.29%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dr. Reddy's Laboratories Ltd ADR
< Previous
1
2
3
4
5
6
Next >
Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar
July 29, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s Q1FY25 Financial Results
July 27, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr Reddy's Laboratories: Q3 Earnings Insights
January 30, 2024
Via
Benzinga
Is NYSE:RDY suited for quality investing?
September 14, 2023
Exploring DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)'s quality characteristics.
Via
Chartmill
Should you consider NYSE:RDY for quality investing?
August 21, 2023
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) may be suited for quality investing, we'll explore why in this article.
Via
Chartmill
Chart Of The Day: What's Cooking At Dr. Reddy's Lab
July 28, 2023
100% technical buy signals 12 new highs and up 10.76% in the last month 38.40+ Weighted Alpha
Via
Talk Markets
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
July 10, 2024
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024
Via
MarketBeat
Should Quality-Oriented Investors Explore DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)?
July 01, 2024
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) can be considered a quality stock. Here's why.
Via
Chartmill
Dr. Reddy's Labs Stock Sees Improved Technical Strength
June 28, 2024
On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76.
Via
Investor's Business Daily
Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M
June 26, 2024
Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for £500 million ($632 million). This strategic move allows Haleon to focus on growth...
Via
Benzinga
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
June 03, 2024
From
Aurigene Pharmaceutical Services Ltd.
Via
Business Wire
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
June 26, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High.
June 03, 2024
Exit polls forecast a landslide win and third consecutive term for Prime Minister Narendra Modi in India's general elections.
Via
Investor's Business Daily
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
May 28, 2024
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024
From
Alvotech
Via
GlobeNewswire
RDY Stock Earnings: Dr Reddy’s Laboratories Beats EPS, Misses Revenue for Q4 2024
May 07, 2024
RDY stock results show that Dr Reddy's Laboratories beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.
Via
InvestorPlace
Dr. Reddy’s Q4 & Full Year FY24 Financial Results
May 07, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
May 03, 2024
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
March 19, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand
February 22, 2024
Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Dr. Reddy’s Q3 & 9M FY24 Financial Results
January 31, 2024
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands
January 03, 2024
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
December 14, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
December 06, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
2 overlooked stocks that crushed earnings but traded lower
November 20, 2023
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results
Via
MarketBeat
Exposures
Product Safety
Dr. Reddy’s Q2 FY24 Financial Results
October 27, 2023
From
Dr. Reddy’s Laboratories Ltd.
Via
Business Wire
Why Quality Investors Should Delve into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) for Investment Opportunities.
October 24, 2023
Reasonable Growth, Debt Levels, and a High ROIC Make DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Appealing to Quality Investors.
Via
Chartmill
Top 5 Health Care Stocks That May Fall Off A Cliff
August 23, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
August 10, 2023
From
Dr. Reddy's Laboratories Ltd.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.